OBJECTIVE: Little is known about the natural history of the HIV infection in men who have sex with men (MSM) in China. METHODS: We compared changes in CD4+ T-cell count and HIV-RNA following seroconversion before starting antiretroviral therapy between MSM in China and in resource-rich countries using data from the Beijing PRIMO cohort and Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE), respectively. Linear mixed models were used to compare rates of CD4 decline (cubic root scale) and changes in HIV-RNA (log10 scale) in the first 3 years following seroconversion. RESULTS: For 131 PRIMO and 3171 CASCADE MSM infected in 2001-2010, estimated CD4+ T-cell count at seroconversion was lower in PRIMO (504 cells/mm3; 95% confidence interval: 463 to 547) compared with CASCADE (554 cells/mm3; 544 to 564). CD4 decline was significantly faster for PRIMO men [-0.59 (-0.72 to -0.47) and - 0.41 (-0.44 to -0.38) cubic root of CD4 count/year for PRIMO and CASCADE, respectively], even after restricting to subtype B (P = 0.01). HIV-RNA at seroconversion was lower in PRIMO compared with CASCADE MSM [difference 0.425 log10/mL (0.249 to 0.603), P < 0.001]. After the first year of seroconversion, PRIMO MSM experienced a faster increase in HIV-RNA [0.830 log10/mL per year; (0.484 to 1.168)] compared with CASCADE MSM [0.018 (-0.035 to 0.067)] (P < 0.001). CONCLUSIONS: CD4 decline and HIV-RNA increase are faster between MSM in China compared with MSM from resource-rich settings. Whether this is due to differences in host immunity or viral characteristics requires further exploration.
OBJECTIVE: Little is known about the natural history of the HIV infection in men who have sex with men (MSM) in China. METHODS: We compared changes in CD4+ T-cell count and HIV-RNA following seroconversion before starting antiretroviral therapy between MSM in China and in resource-rich countries using data from the Beijing PRIMO cohort and Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE), respectively. Linear mixed models were used to compare rates of CD4 decline (cubic root scale) and changes in HIV-RNA (log10 scale) in the first 3 years following seroconversion. RESULTS: For 131 PRIMO and 3171 CASCADE MSM infected in 2001-2010, estimated CD4+ T-cell count at seroconversion was lower in PRIMO (504 cells/mm3; 95% confidence interval: 463 to 547) compared with CASCADE (554 cells/mm3; 544 to 564). CD4 decline was significantly faster for PRIMO men [-0.59 (-0.72 to -0.47) and - 0.41 (-0.44 to -0.38) cubic root of CD4 count/year for PRIMO and CASCADE, respectively], even after restricting to subtype B (P = 0.01). HIV-RNA at seroconversion was lower in PRIMO compared with CASCADE MSM [difference 0.425 log10/mL (0.249 to 0.603), P < 0.001]. After the first year of seroconversion, PRIMO MSM experienced a faster increase in HIV-RNA [0.830 log10/mL per year; (0.484 to 1.168)] compared with CASCADE MSM [0.018 (-0.035 to 0.067)] (P < 0.001). CONCLUSIONS: CD4 decline and HIV-RNA increase are faster between MSM in China compared with MSM from resource-rich settings. Whether this is due to differences in host immunity or viral characteristics requires further exploration.
Authors: George Alemnji; Peter Fonjungo; Barbara Van Der Pol; Trevor Peter; Rami Kantor; John Nkengasong Journal: AIDS Patient Care STDS Date: 2014-04-17 Impact factor: 5.078
Authors: Marina B Klein; Jim Young; David Dunn; Bruno Ledergerber; Caroline Sabin; Alessandro Cozzi-Lepri; Francois Dabis; Richard Harrigan; Darrell H Tan; Sharon Walmsley; John Gill; Curtis Cooper; Alexandra U Scherrer; Amanda Mocroft; Robert S Hogg; Fiona Smaill Journal: CMAJ Open Date: 2014-10-01
Authors: Yanink Caro-Vega; Carlos del Rio; Viviane Dias Lima; Malaquias Lopez-Cervantes; Brenda Crabtree-Ramirez; Sergio Bautista-Arredondo; M Arantxa Colchero; Juan Sierra-Madero Journal: PLoS One Date: 2015-08-24 Impact factor: 3.240